From Our Partners
Wednesday, July 6, 2022
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Industry News

Vaccine Technology Achieves One-Year Thermostability Milestone

by Global Biodefense Staff
January 15, 2014

Soligenix, Inc. announced today significant steps forward in the development of ThermoVax, its proprietary vaccine thermostabilization platform technology. Recent studies have demonstrated the potential for heat-sensitive vaccines formulated using this technology to withstand temperatures exceeding 40 degrees Celsius (104 degrees Fahrenheit) for up to one year.

The underlying work has been conducted with the company’s proprietary ricin toxin vaccine (RiVax) as part of a continuing program to evaluate the effectiveness of protein subunit vaccines to withstand extremes of temperature and other environmental stress conditions.

These studies amplify and extend former evaluations that indicated retention of potency for at least six months at temperatures as high as 40 degrees Celsius, outside the range of typical vaccine storage conditions. The research and development of ThermoVax is currently being supported by a $9.4 million National Institute of Allergy and Infectious Disease (NIAID) grant to Soligenix for biodefense vaccines to prevent ricin toxin and anthrax exposure.

These results underline the potential for long-term stability of subunit vaccines stored under ambient conditions or at high temperatures. Vaccines are almost always stored refrigerated because of vulnerability to heat exposure, resulting in loss of potency and efficacy. By employing ThermoVax during final formulation of RiVax, which is extremely unstable in its liquid form, a stable and potent vaccine is produced that is capable of withstanding temperatures at least as high as 40 degrees Celsius for up to one year. The most recent studies, which employed a combination of sensitive techniques to evaluate the structure of the vaccine and the resulting immunogenicity, demonstrated that the vaccine retained original levels of potency after one year of storage at 40 degrees Celsius. RiVax, formulated with ThermoVax, has the potential to facilitate easier storage and distribution in a national stockpile for emergency situations.

In addition to RiVax, the Company has previously reported that its proprietary anthrax vaccine, VeloThrax, formulated with ThermoVax and subsequently exposed to temperatures as high as 70 degrees Celsius (158 degrees Fahrenheit) for at least one month, retained full potency in animals as well as other characteristics such as receptor binding indicative of full structural integrity. The combination of ThermoVax and VeloThrax along with a potent secondary adjuvant resulted in rapid onset of antibodies correlated to protection against anthrax in animal models. Additional studies have confirmed longer term stability of VeloThrax at 40 degrees Celsius for up to four months.

“The success attained thus far with both ThermoVax formulated RiVax  and ThermoVax formulated VeloThrax  further demonstrates the robustness and broad applicability of the ThermoVax  technology,” stated Christopher J. Schaber, PhD, President and Chief Executive Officer of Soligenix. “We believe that ThermoVax  could be applied to a wide variety of vaccines and adjvuants to eliminate the need for refrigeration and cold chain distribution.

Dr. Schaber continued, “We believe ThermoVax is a significant step forward in vaccine technology and has the potential to lead to major cost savings in the distribution and storage of currently marketed vaccines and could further facilitate their use in the developing world. We remain excited about the potential utility of the ThermoVax platform and have initiated discussions with a number of vaccine companies and non-profit organizations regarding the potential for collaboration on heat stable versions of their vaccine candidates.”

ThermoVax, RiVax, VeloThrax and OrbeShield are each trademarked by Soligenix.

From Our Partners
Tags: Animal ModelsAnthraxRicinStrategic National StockpileThermostabilityVaccines

Related Posts

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control
Medical Countermeasures

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022
Biodefense Industry News
Industry News

Tonix Pharmaceuticals Opens Advanced Development Center for Vaccine Programs

June 20, 2022
Monkeypox Cases Prompt Additional Contracts for Bavarian Nordic Vaccine
Medical Countermeasures

Monkeypox Cases Prompt Additional Contracts for Bavarian Nordic Vaccine

May 30, 2022
Novavax Missed Its Global Moonshot but Is Angling to Win Over mRNA Defectors
Industry News

Novavax Missed Its Global Moonshot but Is Angling to Win Over mRNA Defectors

May 26, 2022
Load More

Latest News

Biodefense Headlines – 5 July 2022

Biodefense Headlines – 5 July 2022

July 5, 2022
Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

June 22, 2022
Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

June 22, 2022
UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC